Source:Dainik Bhaskar
Subject: Science and Technology (Biotechnology, Animal Health) and Indian Economy (Agriculture, Livestock)|Target exams: MPPSC, MPESB
Key points for Prelims: H5N1 avian influenza, Inactivated vaccine, ICAR-NIHSAD, Clade 2.3.2.1a, Zoonotic disease
Mains syllabus mapping
- General Studies Paper 3: Science and Technology: indigenous development of vaccines and biotechnology; Animal health and zoonotic diseases; Agriculture: livestock and poultry sector
- General Studies Paper 2: Health: government institutions and disease control; Indian Council of Agricultural Research and its role in research institutions
Key facts for one-day exams
- The indigenous H5N1 vaccine was developed in Bhopal.
- The vaccine is intended for chickens.
- The vaccine uses inactivated H5N1 clade 2.3.2.1a.
- The vaccine launch is planned for 20 November 2026.
- The National Institute of High Security Animal Diseases is an Indian Council of Agricultural Research institute.
Indigenous H5N1 poultry vaccine: why in the news?
The planned launch of India’s first indigenous H5N1 poultry vaccine on 20 November 2026 marks a scientific achievement in animal health and disease control, with potential to protect the poultry sector and reduce zoonotic risks.
India’s first indigenous inactivated H5N1 avian influenza vaccine for chickens has been developed in Bhopal. The Indian Council of Agricultural Research-National Institute of High Security Animal Diseases (ICAR-NIHSAD) developed the vaccine, and its launch is planned for 20 November 2026. Union Agriculture Minister Shivraj Singh Chouhan is expected to launch the vaccine on that date. The vaccine is intended to protect poultry from bird flu and reduce economic losses for farmers.
The vaccine was developed using inactivated highly pathogenic avian influenza H5N1 clade 2.3.2.1a. All technical tests of the vaccine have been completed, officials said. Bird flu outbreaks can lead to culling of chickens, disruption of farm production and financial losses for poultry businesses. Reducing the risk of animal-to-human transmission is another intended benefit of the vaccine.
What is the vaccine and how was it developed?
The vaccine is an inactivated H5N1 avian influenza vaccine, meaning it uses a pathogen that has been inactivated so it cannot replicate, while retaining components that stimulate an immune response. It was developed using the highly pathogenic H5N1 clade 2.3.2.1a virus. The ICAR-NIHSAD in Bhopal conducted the research and development over a long period.
What are the intended benefits for poultry and public health?
The vaccine is intended to protect chickens from bird flu, which can cause culling of birds, production disruption and financial losses for poultry businesses and farmers. By controlling the disease in poultry, the vaccine may also reduce the risk of zoonotic transmission of the virus from animals to humans, though this is an intended benefit and not a demonstrated outcome of deployment.
What is the next step after the planned launch?
The planned launch on 20 November 2026 follows completion of technical tests. Effective poultry protection will depend on how vaccination is deployed alongside disease surveillance and farm biosecurity measures.
Madhya Pradesh connection
Key terms
- Avian influenza:
- Avian influenza is an infectious disease caused by influenza viruses that primarily affect birds.
- Inactivated vaccine:
- An inactivated vaccine uses a pathogen that has been inactivated so it cannot replicate, while retaining components that stimulate an immune response.
- Clade:
- A clade is a group of organisms or viruses that share a common ancestor.
- Zoonotic transmission:
- Zoonotic transmission is the spread of an infectious agent between animals and humans.
Indigenous H5N1 poultry vaccine: why it matters for exams
Exams: MPPSC, MPESB
Syllabus: Science and Technology: Vaccines and infectious diseases; Agriculture: Animal husbandry and poultry health
Common mistake: Examiners may present the vaccine as a live H5N1 vaccine or its planned launch as completed; it is inactivated and its launch was planned for 20 November 2026.
Mains practice questions
Question 1(GS-3 | 250 words | 15 marks)
Discuss the significance of India’s indigenous H5N1 poultry vaccine developed by ICAR-NIHSAD for the poultry sector, farmers and public health. What challenges must be addressed for its effective implementation?
Answer outline
- Introduction: Open by noting that India’s first indigenous inactivated H5N1 vaccine, developed in Bhopal and slated for launch on 20 November 2026, marks a shift from import dependence to self-reliance in animal health.
- Body:
- Benefits to the poultry sector: protection against bird flu, reduction in culling and production losses, and financial stability for farmers.
- Public health dimension: reducing the risk of animal-to-human (zoonotic) transmission of avian influenza, linking One Health principles.
- Indigenous capability: role of ICAR-NIHSAD and the completion of technical tests, showing strengthened biotechnology and vaccine research.
- Implementation challenges: ensuring cold-chain storage and distribution to rural and small poultry farms, farmer awareness and affordability, vaccination surveillance and monitoring of circulating strains.
- Need for coordination between agriculture and health ministries, and regulatory clearance and quality assurance for scaling up production.
- Conclusion: A balanced way forward combines timely launch with robust distribution, farmer outreach and surveillance so that the vaccine delivers both economic and public health gains.
Question 2(GS-3 | 150 words | 10 marks)
Critically examine the role of indigenous vaccine development in strengthening India’s livestock sector and disease control preparedness.
Answer outline
- Introduction: Frame the issue with the planned 20 November 2026 launch of an indigenous inactivated H5N1 vaccine for chickens, developed by ICAR-NIHSAD in Bhopal, as an example of domestic research capacity.
- Body:
- Strengths: reduced import dependence, tailored response to locally circulating strains such as clade 2.3.2.1a, and faster outbreak response.
- Limitations: vaccine efficacy must be proven in field conditions, and vaccination alone does not replace biosecurity and culling protocols.
- Preparedness gaps: need for sustained funding, scale-up of manufacturing and integration with disease surveillance systems.
- Conclusion: Indigenous vaccines are a vital tool, but their impact depends on field deployment, surveillance and farmer participation within a broader One Health framework.
Stuck? Get it in one tap
Bird flu is an infection that can harm chickens and disrupt poultry farming. Researchers in Bhopal developed a vaccine using an inactivated H5N1 virus, which cannot replicate. The vaccine is intended to protect chickens, and its launch is planned for 20 November 2026.
- Science and Technology: Vaccines and infectious diseases
- Agriculture: Animal husbandry and poultry health
Related concepts: Avian influenza, Inactivated vaccine, Clade, Zoonotic transmission
Practice questions
Pick an answer, then read the explanation.
- Q1Hard
Consider the following statements about India’s indigenous H5N1 poultry vaccine:
- 1.It was developed using an inactivated virus.
- 2.It is intended to protect chickens.
- 3.Its launch was planned for 20 November 2026.
Which of the statements given above is/are correct?
Explanation: All three statements are correct: the vaccine is inactivated, targets chickens and was planned for launch on 20 November 2026. A planned launch is distinct from a completed launch.
- Q2Medium
Which H5N1 clade was used to develop the indigenous poultry vaccine in Bhopal?
Explanation: The vaccine was developed from inactivated highly pathogenic H5N1 of clade 2.3.2.1a. The other numerical designations differ from the specified clade.
- Q3Medium
What is the primary intended benefit of the indigenous H5N1 vaccine developed in Bhopal?
Explanation: The inactivated H5N1 vaccine is intended to protect chickens from bird flu. Its purpose is vaccination of poultry, rather than human treatment, feed improvement or replacement of surveillance.
Frequently asked questions
1. Where was India’s indigenous H5N1 poultry vaccine developed?
The vaccine was developed at the Indian Council of Agricultural Research-National Institute of High Security Animal Diseases in Bhopal.
2. Which virus clade was used in the Bhopal H5N1 vaccine?
The vaccine was developed using inactivated highly pathogenic H5N1 clade 2.3.2.1a.
3. When is the indigenous H5N1 poultry vaccine planned for launch?
The launch is planned for 20 November 2026.
4. What is the indigenous H5N1 vaccine intended to protect?
The vaccine is intended to protect chickens against avian influenza.
All sources
Original18 November 2026 · Read story

